Pharnext

Pioneering PLEOTHERAPY™ for neurodegenerative diseases

Issy-les-Moulineaux, France · Founded 2007 · $95.3M raised

Employees
11–50
Founded
2007
Business Model
B2B
Total Funding
$95.3M
Last Round
$90.0M Convertible NoteJun 2021
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Pharnext is an advanced clinical-stage biopharmaceutical company founded in 2007 by renowned scientists including Professor Daniel Cohen, a pioneer of modern genomics. The company develops novel therapeutics for orphan and common neurodegenerative diseases — including Charcot-Marie-Tooth disease type 1A, Alzheimer's disease, Parkinson's disease, and ALS — for which there are currently no cures. Pharnext pioneered PLEOTHERAPY™, a new drug discovery paradigm using network pharmacology and genomic data to identify synergistic combinations of already-approved drugs repurposed at optimal doses for new indications. Its lead candidate PXT3003 showed positive Phase 2 and Phase 3 results in CMT1A, and PXT864 generated encouraging Phase 2 data in Alzheimer's disease.

Summary

Pharnext is a Biotech company based in Issy-les-Moulineaux, France, founded in 2007. It has raised $95.3M in total across 2 rounds, most recently a $90.0M Convertible Note round in Jun 2021. Investors include IPF Partners and Truffle Capital.

Funding History

ConvertibleConvertible NoteJun 2021
$90.0M

Sign up to see all 3 events

Funding: Convertible Note. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Pharnext on Indexed.vc
<a href="https://indexed.vc/companies/pharnext"><img src="https://indexed.vc/api/badge/company/pharnext" alt="Pharnext on Indexed.vc" width="260" height="76" /></a>